Glaxosmithkline Pharmaceuticals
Market cap ₹44,693 Cr
- P/E
- 38.98
- Day range
- ₹2,620.20 – ₹2,699.00
- 52-week range
- ₹2,088.10 – ₹3,120.70
- Volume
- 87,837
- Open
- ₹2,698.80
- Prev close
- ₹2,687.60
Latest results · Q2 FY27(consolidated)Revenue ₹1,184 Cr+20.8%Profit ₹336 Cr+30.4%Margin 28.4%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
GLAXO in NSE indices and F&O
Research profile
Composite 69 / 100Factor percentiles
Derived metrics
- Earn. yield
- 2.6%
- Graham no.
- ₹405.86
- vs Graham
- -84.6%
- ROE ÷ P/B
- 2.0%
- 12-1 mom.
- +1.0%
- Return / vol
- 0.15
- Magic Formula
- #117
- FCF yield
- 1.9%
Appears in 12 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Glaxosmithkline PharmaceuticalsGLAXO | ₹44,693 Cr | 38.98 | 24.08 | 49.1% | 61.0% | 34.0% | 0.02 | +20.8% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 2d agoHeadlines about Glaxosmithkline Pharmaceuticals from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 39.4
- Price / Book
- 23.77
- ROE (FY26)
- 49.1%
- ROCE (latest year)
- 61%
- Dividend yield
- 2.16%
Moving averages (NSE)
- 20-day
- ₹2,556.76
- Price above
- 50-day
- ₹2,674.42
- Price below
- 200-day
- ₹2,528.99
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- Public
- DII
- FII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the bonus of 11 Sept 2018: earlier bars are per pre-bonus share.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 805 | 930 | 815 | 1,011 | 949 | 974 | 805 | 980 | 1,041 | 995 | 938 | 1,184 |
| YoY Sales growth | — | — | — | — | — | — | -1 | -3 | — | — | — | — |
| Expenses | 587 | 673 | 584 | 689 | 658 | 641 | 554 | 644 | 670 | 644 | 643 | 782 |
| Operating Profit | 218 | 257 | 231 | 322 | 292 | 333 | 251 | 336 | 371 | 351 | 296 | 402 |
| OPM % | 27% | 28% | 28% | 32% | 31% | 34% | 31% | 34% | 36% | 35% | 31% | 34% |
| Other Income | -135 | 32 | 36 | 39 | 35 | 41 | 44 | 36 | 50 | 36 | 44 | 73 |
| Interest | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 |
| Depreciation | 17 | 18 | 16 | 17 | 19 | 15 | 16 | 17 | 20 | 13 | 16 | 15 |
| Profit before tax | 65 | 271 | 249 | 344 | 308 | 359 | 279 | 354 | 400 | 373 | 322 | 459 |
| Tax % | 30% | 28% | 27% | 27% | 25% | 27% | 27% | 27% | 26% | 26% | 26% | 27% |
| Net Profit | 46 | 194 | 182 | 252 | 230 | 263 | 205 | 257 | 296 | 278 | 237 | 336 |
| EPS in Rs | ₹2.70 | ₹11.48 | ₹10.76 | ₹14.91 | ₹13.57 | ₹15.52 | ₹12.10 | ₹15.20 | ₹17.45 | ₹16.40 | ₹14.00 | ₹19.83 |
From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-1 days since Mar 2021
-35 days since Mar 2021
+19 days since Mar 2021
-54 days since Mar 2021
-52 days since Mar 2021
Strengths, risks & growth
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)
Strengths
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 43.5%
- Company has been maintaining a healthy dividend payout of 94.6%
Risks
- Stock is trading at 23.8 times its book value
- The company has delivered a poor sales growth of 5.49% over past five years.
Compounded Sales Growth
- 10 Years
- +3%
- 5 Years
- +5%
- 3 Years
- +6%
- TTM
- +12%
Compounded Profit Growth
- 10 Years
- +10%
- 5 Years
- +15%
- 3 Years
- +18%
- TTM
- +19%
Stock Price CAGR
- 10 Years
- +7%
- 5 Years
- +10%
- 3 Years
- +17%
- 1 Year
- +5%
Return on Equity
- 10 Years
- +33%
- 5 Years
- +48%
- 3 Years
- +43%
- Last Year
- +46%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 75.00% | 75.00% | 75.00% | 75.00% | 0.00 pp |
| FII | 4.63% | 4.62% | 4.79% | 4.75% | -0.04 pp |
| DII | 7.70% | 7.68% | 7.81% | 8.47% | +0.66 pp |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00 pp |
| Public | 12.67% | 12.69% | 12.42% | 11.77% | -0.65 pp |
Filed with NSE for Sept 2026: promoters 75.00%, public 25.00%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 6.07% (+1.20 pp)- Promoters75.0%
- Foreign institutions4.8%
- Mutual funds6.1%
- Insurance2.3%
- Other domestic institutions0.1%
- Retail9.5%
- Others2.3%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| SBI Midcap Fund | 0.66% | 1.32% | +0.01 pp |
| Kotak Large & Mid Cap Fund | 0.61% | 0.89% | -0.02 pp |
| Nippon India Pharma Fund | 0.57% | 2.83% | +0.17 pp |
| Quant Mid Cap Fund | 0.49% | 2.97% | +2.64 pp |
| Nippon India Growth Mid Cap Fund | 0.32% | 0.29% | -0.01 pp |
Scorecard
- Performance
- Avg
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 26.1%
- Downside volatility
- 25.4%
- Worst 5% of days
- 2.8%
- Average of that tail
- 3.5%
- Max drawdown (1Y)
- 26.6%
- Below its peak
- 15.1%
Against the market
- Beta vs Nifty 50
- 0.46
- Correlation
- 0.24
- Relative strength (3M)
- -6.3%
- ATR (14)
- 3.1%
Return
- Return 1M
- +2.8%
- Return 3M
- -2.4%
- Return 6M
- +10.4%
- Return 1Y
- +3.9%
- vs 200-day average
- +4.3%
Momentum
- RSI (14)
- 52.3
- MACD histogram
- 23.09
- Stochastic %K
- 54.7
- ADX (14)
- 21.3
- +DI / −DI
- 25.2 / 18.7
- Money flow index
- 60.4
Participation
- Delivery (20d avg)
- 56.4%
- vs its 60-day baseline
- +4.5 pts
- Volume vs 20-day
- -0.1σ
- Close vs day's VWAP
- -0.8%
- 52-week position
- 53 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
No F-Score: it needs two reporting periods a year apart that carry both an income statement and a balance sheet, and this company's filings do not yet line up that way. The ratios below need only the one period and are unaffected.
- Free cash flow
- ₹848 Cr
- FCF yield
- 1.9%
- Cash conversion
- 0.87
- Accruals ratio
- 0.031
- Net debt
- -₹612 Cr
- Net debt / equity
- -0.33
- EV / sales
- 10.60
- Capex intensity
- 1.4%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividend₹57.00
Dividend - Rs 57 Per Share
29 May 2026ex-date - dividend₹42.00
Dividend - Rs 42 Per Share
30 May 2025ex-date - dividend₹12.00
Interim Dividend - Rs 12 Per Share
7 Nov 2024ex-date - dividend₹32.00
Dividend - Rs 32 Per Share
31 May 2024ex-date - dividend₹32.00
Dividend - Rs 32 Per Share
30 Jun 2023ex-date - dividend₹30.00
Dividend - Rs 30 Per Share/Special Dividend- Rs 60 Per Share
7 Jul 2022ex-date - dividend₹30.00
Annual General Meeting/Dividend - Rs 30 Per Share
19 Jul 2021ex-date - dividend₹20.00
Dividend - Rs 20 And Special Dividend - Rs 20 Per Share
17 Jul 2020ex-date - dividend₹20.00
Annual General Meeting/Dividend Rs 20 Per Share
11 Jul 2019ex-date - bonusNot available — not reported in this filing
Bonus 1:1
11 Sept 2018ex-date - dividend₹35.00
Dividend- Rs 35 Per Share
13 Jul 2018ex-date - dividend₹30.00
Dividend - Rs 30/- Per Share
14 Jul 2017ex-date - dividend₹50.00
Dividend Rs 50/- Per Share
15 Jul 2016ex-date - dividend₹62.00
Annual General Meeting/Dividend - Rs 62..50/- Per Share
23 Jul 2015ex-date - dividend₹50.00
Final Dividend Rs.50/- Per Share
3 Apr 2014ex-date - dividend₹50.00
Dividend Rs. 50 Per Share
4 Apr 2013ex-date - dividend₹45.00
Dividend Rs.45/- Per Share
29 Mar 2012ex-date - dividend₹40.00
Dividend-Rs.40/- Per Share
14 Mar 2011ex-date - dividend₹30.00
Dividend-Rs.30/- Pr Share
10 Mar 2010ex-date - otherNot available — not reported in this filing
Div Fin-Rs.22 + Spl-Rs.18
18 Mar 2009ex-date
Company announcements
Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve As per attachment
As per attachment
As per attachment
As per attachment
Outcome of Postal Ballot
As per attachment
As per attachment
As per attachment
The Exchange has sought clarification from GlaxoSmithKline Pharmaceuticals Ltd on August 26, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
As per attachment
As per attachment
As per attachment
Transcript
IT Refund of Rs 52 crores
As per attachment
Filed with BSE (scrip 500660); the last 45 days. Documents open at bseindia.com.
SEBI filings & orders
From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.
Buybacks, open offers & rights issues
- Open offer
GlaxoSmithkline Pharmaceuticals Limited
26 Dec 2013Read on SEBI
Documents
Annual reports
Earnings calls
- Nov 2026SlidesRecording
- Aug 2026TranscriptSlides
- Jun 2026TranscriptSlides
- Feb 2026TranscriptSlidesRecording
- Nov 2025Slides
- Aug 2025TranscriptSlides
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 4 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Glaxosmithkline Pharmaceuticals: common questions
Answered from the figures on this page.